Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990;14(11-12):967-73.
doi: 10.1016/0145-2126(90)90109-m.

Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study

D Macdonald  1 , Y Z Jiang, A A Gordon, P Mahendra, R Oskam, P A Palmer, C R Franks, A J Barrett
Affiliations

Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study

D Macdonald et al. Leuk Res. 1990.

Abstract

We treated nine patients in first remission from AML with rhIL-2. The toxic effects of rhIL-2 infusion were, malaise, pyrexia, and hypotension, which resolved rapidly on cessation of rhIL-2 infusion. No patient required transfer to an intensive care unit. Following rhIL-2 infusions patients developed eosinophilia, and a modest lymphocytosis, involving both NK cells, and T lymphocytes. Relapse occurred in six patients at a median of 39 weeks from remission. A particular concern was rapid relapse in the two patients with AML FAB type M5. There was no survival advantage from rhIL-2 treatment when compared to a similar group of chemotherapy only treated AML patients from this institution.

PubMed Disclaimer

Publication types

MeSH terms